Deuterated DMT Solid Dosage Forms for Psychiatric Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current administration protocols for DMT-based therapies are limited by short duration of action and risk of toxic buildup in poor metabolizers, necessitating the development of a more flexible and safe therapeutic approach to maintain a psychedelic experience for psychiatric disorders.
Innovation Solution
The use of solid dosage forms comprising mixtures of N,N-dimethyltryptamine and its deuterated analogues, specifically α,α-dideutero-N,N-dimethyltryptamine and α-protio, α-deutero-N,N-dimethyltryptamine, to control pharmacokinetic profiles and achieve a therapeutically optimized duration without infusion protocols or MAOIs, allowing for a finely tuned psychedelic experience.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If DMT is administered to achieve therapeutic psychedelic effect, then psychiatric disorders can be treated, but the duration of action is too short (under 20 minutes) to maintain effective therapy
Solution Approach 1:
The patent applies kinetic isotope effect by substituting hydrogen with deuterium at the alpha position of DMT, which changes the metabolic rate parameter. This deuteration slows down the metabolism of DMT, thereby extending its duration of action from under 20 minutes to a therapeutically optimized duration while maintaining reliable therapeutic effectiveness
2Duration of action of moving object
If infusion protocols are used to extend DMT experience duration, then therapeutic duration is improved, but risk of toxic buildup increases in poor metabolizers
Solution Approach 1:
The patent modifies the metabolic parameter of DMT through alpha-position deuteration, creating a compound with inherently extended half-life. This allows for a single oral dose to maintain therapeutic levels throughout the required duration without needing repeated infusions, thereby eliminating the risk of toxic buildup in poor metabolizers while achieving the desired extended duration
3Duration of action of moving object
If MAOIs are combined with DMT to extend duration, then therapeutic duration is improved, but treatment complexity and safety risks increase
Solution Approach 1:
The patent uses kinetic isotope effect through deuteration to intrinsically extend DMT's half-life, eliminating the need for combination therapy with MAOIs. This simplifies the treatment protocol to a single substance administration while achieving the desired extended duration, thereby reducing treatment complexity and associated safety risks
4Ease of operation
If single dose administration is used to simplify treatment, then ease of operation is improved, but ability to maintain full dissociation ('breakthrough') for optimized duration is compromised
Solution Approach 1:
The patent modifies the pharmacokinetic parameters of DMT through alpha-position deuteration, which extends the half-life sufficiently to maintain full dissociation ('breakthrough') state for a therapeutically optimized duration. This enables single dose administration to achieve both ease of operation and sustained therapeutic effect without requiring complex protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions provide a clinically applicable and flexible administration of DMT-induced psychedelic-assisted psychotherapy, achieving plasma concentrations suitable for either sub-breakthrough or breakthrough experiences, thereby treating psychiatric disorders effectively and safely.
Implementation Method 1
α,α,β,β-Tetradeutero-N,N-dimethyltryptamine is known to exhibit a kinetic isotope effect, which bestows a significant difference on its in vivo pharmacokinetic profile as compared with N,N-dimethyltryptamine. Substitution of hydrogen with a deuterium at an sp3 carbon centre is known to give rise to a 'kinetic isotope effect' by virtue of the difference in bond strength between a CH and a CD bond
Data Source
AI summary
The present invention relates to a solid dosage form comprising two or more compounds selected from N,N-dimethyltryptamine and its deuterated analogues and pharmaceutically acceptable salts thereof, and methods of treatment (e.g., of a psychiatric disorder or a neurological disorder) comprising administering the solid dosage form to a patient in need thereof.